Search results for "Estro."
showing 10 items of 770 documents
Aggiornamento del Commento sistematico del Titolo IV, libro XI CPP.
2019
Il commento aggiornato (artt. 730, 731, 732, 733, 734, 734-bis, 735, 735-bis, 736, 737, 737-bis, 738, 739,740, 740-bis, 740- ter, 741, 742, 742-bis, 743, 744, 745, 746, 746-bis, 746-ter, 746-quater) analizza le norme codicistiche alla luce delle più recenti innovazioni legislative dettate in tema di trasferimento dei procedimenti penali (d.lgs. 3.10.2017, n. 149) e delle più significative decisioni giurisprudenziali.
Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive b…
2021
Abstract Breast Cancer (BC) is a leading cause of death in women, currently affecting 13% of female population worldwide. First-line clinical treatments against Estrogen Receptor positive (ER+) BC rely on suppressing estrogen production, by inhibiting the aromatase (AR) enzyme, or on blocking estrogen-dependent pro-oncogenic signaling, by targeting Estrogen Receptor (ER) α with selective Modulators/Degraders (SERMs/SERDs). The development of dual acting molecules targeting AR and ERα represents a tantalizing alternative strategy to fight ER + BC, reducing the incidence of adverse effects and resistance onset that limit the effectiveness of these gold-standard therapies. Here, in silico desi…
Rational design of allosteric modulators of the aromatase enzyme: An unprecedented therapeutic strategy to fight breast cancer.
2019
Estrogens play a key role in cellular proliferation of estrogen-receptor-positive (ER+) breast cancers (BCs). Suppression of estrogen production by competitive inhibitors of the enzyme aromatase (AIs) is currently one of the most effective therapies against ER + BC. Yet, the development of acquired resistance, after prolonged treatments with AIs, represents a clinical major concern. Serendipitous findings indicate that aromatase may be non-competitively inhibited by clinically employed drugs and/or industrial chemicals. Here, by performing in silico screening on two putative allosteric sites, molecular dynamics and free energy simulations, supported by enzymatic and cell-based assays, we id…
Global gene expression profiles in skeletal muscle of monozygotic female twins discordant for hormone replacement therapy
2010
Summary Aging is accompanied by inexorable loss of muscle tissue. One of the underlying causes for this is the massive change in the hormonal milieu of the body. The role of a female sex steroid – estrogen – in these processes is frequently neglected, although the rapid decline in its production coincides with a steep deterioration in muscle performance. We recruited 54- to 62-year-old monozygotic female twin pairs discordant for postmenopausal hormone replacement therapy (HRT, n = 11 pairs; HRT use 7.3 ± 3.7 years) from the Finnish Twin Cohort to investigate the association of long-term, estrogen-based HRT with skeletal muscle transcriptome. Pathway analysis of muscle transcript profiles r…
Effects of transdermal hormone replacement therapy on levels of soluble P- and E-selectin in postmenopausal healthy women
2002
Abstract Objective: To study the adhesion molecule pattern in postmenopausal women who were not receiving hormone replacement therapy (HRT), HRT users, and fertile women. Design: Case-control study. Setting: Second University of Naples, Naples, Italy. Patient(s): Fifty healthy naturally postmenopausal women and 20 fertile women. Intervention(s): Twenty-six women received no HRT and 24 received continuous transdermal 17β−estradiol, 0.05 mg/d, plus oral acetate nomegestrol, 5 mg/d. Main Outcome Measure(s): Levels of the soluble forms of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, and P-selectin. Result(s): Women who did not received HRT …
Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide
2021
Introduction: Vulvovaginal atrophy (VVA) is a chronic condition caused by estrogen deficiency. It affects around 50% of postmenopausal women, reducing their general and sexual quality of life as well as the quality of their personal relationships. Aim: The aim of this clinical guide is to set out an individualized approach to the management of VVA with topical estrogens and non-hormonal preparations. Materials and methods: Literature review and consensus of expert opinion. Summary recommendations: An individualized approach is required for the management of VVA. Topical low-dose estrogens are effective and also alleviate urinary incontinence and prevent recurrent urinary tract infections. W…
Las obras que nunca se acaban. El mantenimiento de los castillos en la Valencia Medieval: sus protagonistas y sus materiales
2003
A partir del estudio de los cuadernos de cuentas de distintas obras llevadas a cabo en los castillos valencianos a lo largo de los siglos XIV y XV, el objeto del presente artículo es analizar la organización de esas campañas de mantenimiento. De esta manera, se observa en primer lugar la mano de obra, desde los maestros al concurso de personal sin cualificar, en su mayoría jóvenes de la localidad y en algunos casos también mujeres; más tarde se estudian las áreas de abastecimiento de materiales y las estrategias para obtenerlos; y por último se hace un repaso a las obras emprendidas, que sin duda ayudará a comprender la forma y función de estas fortalezas, así como las debilidades de las té…
Protective Effect of Sildenafil against Estradiol-induced ROS production
2010
Several reports suggest that xanthine dehydrogenase (XDH) and its oxidase form (XO) play an important role in various forms of ischemic and vascular injuries. Recently we have demonstrated that 17β-estradiol (E2) induces a significant decrease of the expression and activity of XDH and its conversion to XO in human mammary epithelial cells. E2 is known to induce upregulation of eNOS gene expression in aortic endothelial cells. In light of the ability of XO-derived O2•¯ to combine with •NO to yield ONOO¯, and considering that ONOO¯ converts XDH to XO, it is important to protect tissues against the XO increased activity and ROS increased production, that would in turn react with •NO to augment…
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in pati…
2015
Aim: Breast International Group (BIG) 2-98 is a randomised phase III trial that tested the effect of adding docetaxel, either in sequence to or in combination with anthracycline-based adjuvant chemotherapy, in women with node-positive breast cancer (BC). Here, we present the 10-year final trial safety and efficacy analyses. We also report an exploratory analysis on the predictive value of Ki67 for docetaxel efficacy, in the BIG 2-98 and using a pooled analysis of three other randomised trials. Patients and methods: 2887 patients were randomly assigned in a 2 x 2 trial design to one of four treatments. The primary objective was to evaluate the overall efficacy of docetaxel on disease free su…
The humoral immune system has a key prognostic impact in node-negative breast cancer.
2008
Abstract Estrogen receptor (ER) expression and proliferative activity are established prognostic factors in breast cancer. In a search for additional prognostic motifs, we analyzed the gene expression patterns of 200 tumors of patients who were not treated by systemic therapy after surgery using a discovery approach. After performing hierarchical cluster analysis, we identified coregulated genes related to the biological process of proliferation, steroid hormone receptor expression, as well as B-cell and T-cell infiltration. We calculated metagenes as a surrogate for all genes contained within a particular cluster and visualized the relative expression in relation to time to metastasis with…